Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease

Overview

Journal Diabetes Ther

Specialty Cardiology & Vascular Diseases

Date 2016 Nov 1

PMID 27796904

Citations 7

Authors

Joel Zonszein

Per-Henrik Groop

Affiliations

Soon will be listed here.

Abstract

Introduction: The duration of uncontrolled type 2 diabetes mellitus (T2DM) can adversely impact small and large vessels, eventually leading to microvascular and macrovascular complications. Failure of therapeutic lifestyle changes, monotherapy, and clinical inertia contribute to persistent hyperglycemia and disease progression. The aim was to review the complex pathophysiology of type 2 diabetes and how different oral agents can be used effectively as first-line therapy in combination with metformin, as well as in patients not achieving glycemic goals with metformin therapy.

Methods: For this review, a non-systematic literature search of PubMed, NCBI, and Google Scholar was conducted.

Results: New oral agents have made it possible to improve glycemic control to near-normal levels with a low risk of hypoglycemia and without weight gain, and sometimes with weight loss. Early combination therapy is effective and has been shown to have a favorable legacy effect. A number of agents are available in a single-pill combination (SPC) that provides fewer pills and better adherence. Compared with adding a sulfonylurea, still the most common oral combination used, empagliflozin has been shown to decrease cardiovascular (CV) events in a dedicated CV outcome study, and pioglitazone has been effective in reducing the risk of secondary CV endpoints, whereas sulfonylureas have been associated with an increased risk of CV disease. In those failing metformin, triple oral therapy by adding a non-metformin SPC such as empagliflozin/linagliptin or pioglitazone/alogliptin is a good option for reducing glycated hemoglobin (HbA1c) without significant hypoglycemia.

Conclusion: Clinicians have a comprehensive armamentarium of medications to treat patients with T2DM. Clinical evidence has shown that dual or triple oral combination therapy is effective for glycemic control, and early treatment is effective in getting patients to goal more quickly. Use of SPCs is an option for double or triple oral combination therapy and may result in better adherence.

Citing Articles

A Review of and Its Component, Berberine, as an Antidiabetic and Antioxidant.

Purwaningsih I, Maksum I, Sumiarsa D, Sriwidodo S Molecules. 2023; 28(3).

PMID: 36770960 PMC: 9919506. DOI: 10.3390/molecules28031294.

Upregulation of GLUT4 and PI3K, and downregulation of GSK3 mediate the anti-hyperglycemic effects of proanthocyanidins.

El-Ashmawy N, Khedr E, Alfeky N, Ibrahim A Med Int (Lond). 2023; 2(3):14.

PMID: 36698506 PMC: 9829200. DOI: 10.3892/mi.2022.39.

Meta-Analysis of 11 Heterogeneous Studies regarding Dipeptidyl Peptidase 4 Inhibitor Add-On Therapy for Type 2 Diabetes Mellitus Patients Treated with Insulin.

Shibuki K, Shimada S, Aoyama T J Diabetes Res. 2020; 2020:6321826.

PMID: 33224988 PMC: 7673952. DOI: 10.1155/2020/6321826.

Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c ≤ 6.5% without Increasing Hypoglycemia: Pooled Analysis of Two Randomized Clinical Trials.

Lv Q, Shen J, Miao L, Ye B, Schepers C, Plat A Diabetes Ther. 2020; 11(6):1317-1330.

PMID: 32328953 PMC: 7261297. DOI: 10.1007/s13300-020-00819-9.

Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study.

Kaku K, Kuroda S, Ishida K, Umeda Y Diabetes Obes Metab. 2018; 20(10):2490-2493.

PMID: 29862617 PMC: 6175153. DOI: 10.1111/dom.13397.

References

Hutchins V, Zhang B, Fleurence R, Krishnarajah G, Graham J . A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011; 27(6):1157-68. DOI: 10.1185/03007995.2011.570745. View

Scheen A . Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2014; 54(1):1-21. DOI: 10.1007/s40262-014-0198-2. View

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2014; 38(1):140-9. DOI: 10.2337/dc14-2441. View

Home P, Pocock S, Beck-Nielsen H, Curtis P, Gomis R, Hanefeld M . Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373(9681):2125-35. DOI: 10.1016/S0140-6736(09)60953-3. View

Jurczyk A, DiIorio P, Brostowin D, Leehy L, Yang C, Urano F . Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγ(null) mice treated with alogliptin. Diabetes Metab Syndr Obes. 2013; 6:493-9. PMC: 3864939. DOI: 10.2147/DMSO.S53154. View

Kernan W, Viscoli C, Furie K, Young L, Inzucchi S, Gorman M . Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016; 374(14):1321-31. PMC: 4887756. DOI: 10.1056/NEJMoa1506930. View

Gerich J . Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010; 27(2):136-42. PMC: 4232006. DOI: 10.1111/j.1464-5491.2009.02894.x. View

Bennett W, Maruthur N, Singh S, Segal J, Wilson L, Chatterjee R . Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011; 154(9):602-13. PMC: 3733115. DOI: 10.7326/0003-4819-154-9-201105030-00336. View

Ou S, Shih C, Chao P, Chu H, Kuo S, Lee Y . Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Ann Intern Med. 2015; 163(9):663-72. DOI: 10.7326/M15-0308. View

10.

Yu O, Yin H, Azoulay L . The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death. Can J Diabetes. 2015; 39(5):383-9. DOI: 10.1016/j.jcjd.2015.02.002. View

11.

Schwartz M, Seeley R, Tschop M, Woods S, Morton G, Myers M . Cooperation between brain and islet in glucose homeostasis and diabetes. Nature. 2013; 503(7474):59-66. PMC: 3983910. DOI: 10.1038/nature12709. View

12.

Aroda V, Henry R, Han J, Huang W, DeYoung M, Darsow T . Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther. 2012; 34(6):1247-1258.e22. DOI: 10.1016/j.clinthera.2012.04.013. View

13.

DeFronzo R . Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4):773-95. PMC: 2661582. DOI: 10.2337/db09-9028. View

14.

Gaede P, Lund-Andersen H, Parving H, Pedersen O . Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358(6):580-91. DOI: 10.1056/NEJMoa0706245. View

15.

Goyal A, Nimmakayala K, Zonszein J . Is there a paradox in obesity?. Cardiol Rev. 2014; 22(4):163-70. PMC: 4048872. DOI: 10.1097/CRD.0000000000000004. View

16.

Nathan D, Buse J, Kahn S, Krause-Steinrauf H, Larkin M, Staten M . Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013; 36(8):2254-61. PMC: 3714493. DOI: 10.2337/dc13-0356. View

17.

Gaede P, Vedel P, Larsen N, Jensen G, Parving H, Pedersen O . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348(5):383-93. DOI: 10.1056/NEJMoa021778. View

18.

Ali M, Bullard K, Saaddine J, Cowie C, Imperatore G, Gregg E . Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013; 368(17):1613-24. DOI: 10.1056/NEJMsa1213829. View

19.

Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

20.

Egan A, Blind E, Dunder K, de Graeff P, Hummer B, Bourcier T . Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med. 2014; 370(9):794-7. DOI: 10.1056/NEJMp1314078. View